GRDN
Guardian Pharmacy ServicesBAI scenario view
RankAlpha Sentiment CodexPost-earnings T+1AI sentiment snapshot
AI commentary
Primary earnings evidence is positive, with raised guidance and strong adjusted EBITDA growth. The stock was reported by the finance feed at $44.11 on August 7, up 11.8% from the prior close, indicating a favorable immediate market reaction. Analyst revisions and social coverage are unavailable, so conviction remains moderate rather than high.
Evidence flagged
No evidence quality warning is currently attached to this memo.
AI events
Q2 revenue was $351.8M, adjusted EBITDA $29.7M, and diluted EPS $0.34; management raised FY2026 revenue guidance to $1.43B-$1.45B and adjusted EBITDA guidance to $129M-$131M. [#SEC-8K-2026-08-06]
Management said IRA-related pricing reductions constrained reported revenue growth to 2%, although underlying revenue growth would have been low double digits absent the reductions. Ongoing payor and reimbursement changes remain a downside risk. [#SEC-8K-2026-08-06]
Residents served reached approximately 210,000, up 8% year over year. The company also completed the Wellness Concepts acquisition and launched a Lexington, Kentucky greenfield pharmacy. [#SEC-8K-2026-08-06]
Recommendation
No formal recommendation provided.

